Can-Fite BioPharma Ltd Stock News

Can-Fite BioPharma (CANF), a clinical-stage biopharmaceutical company, is trading ~3% lower in the pre-market Tuesday after announcing a delay for a key data readout for the company’s…

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis 

Summary We are CORRECTING our initiating coverage of Can-Fite BioPharma Ltd. (“Can Fite” or the “company”), a clinical-stage pharmaceutical company, with an OUTPERFORM rating and $6.00 price target (CORRECTION from the previous, initiated $2 price target). With a pipeline of proprietary small molecule drugs treating inflammation, cancer and liver diseases, we believe Can-Fite is poised to register material progress in commercializing its compounds in 2022, including the imminent release of Phase III trial data for the treatment of psoriasis. Further, with a business model predicated on licensing compounds to leading international pharmaceutical players, we believe new contracts and territory expansion will refocus investors on Can-Fite’s myriad positives. As such, we view the risk/reward in CANF as impressive and are initiating coverage with an OUTPERFORM rating and a $6.00 price target. Key Points Focused on A3 adenosine receptor (“A3AR”) . A3AR has a high incidence in cancer and inflammatory cells, which allows the company’s compounds to target A3AR and destroy the corresponding cells.

Can-Fite BioPharma (CANF) enrolled the first patient in a phase 2b study of its drug namodenoson to treat non-alcoholic steatohepatitis ((NASH))

Here is how CanFite Biopharma Ltd (CANF) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

Can-Fite BioPharma (CANF) announces that pre-clinical studies with skin cells, modeling psoriasis in humans, show that Piclidenoson destroys pathological skin cells.The

Can-Fite (CANF) files patent applications in several countries for treating all advanced solid tumors. The filing comes after Can-Fite's drug cleared all tumor lesions in advanced liver cancer.

Can-Fite BioPharma Ltd. Sponsored ADR (CANF) shares closed today 15.1% higher than it did at the end of yesterday. The stock is currently down 29.2% year-to-date, down 31.5% over the past 12 months, and down 96.5% over the past five years. Today, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 0.1%. Trading Activity Shares traded as high as $1.79 and as low as $1.21 this week.Shares closed 67.0% below its 52-week high and 54.2% above its 52-week low.Trading volume this week was 94.9% lower than the 10-day average and 83.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at -0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around?

These penny stocks are on the move, early and here's why. The post Hot Penny Stocks To Watch Before Today's Opening Bell appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

Grab Holdings Limited Class A Ordinary Shares (NASDAQ:GRAB) with the stream of 0.00% also noticed, India Can-Fite BioPharma Ltd. (AMEX:CANF) encountered a rapid change of -32.09% in the last hour The post Market Mover: Grab Holdings Limited Class A Ordinary Shares (NASDAQ:GRAB), Can-Fite BioPharma Ltd. (AMEX:CANF) appeared first on Stocks Equity .

Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer.

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson experienced a Complete Re

The stock price of Can Fite Biopharma (NYSEAMERICAN: CANF) increased by over 70% during intraday trading today. This is why it happened.